Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Egalet Ramps Up Commercial Ahead Of Abuse-Deterrent Pain Drug Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma has relaunched two drugs for pain – Sprix and Oxaydo – supported by a 50-person sales team, laying the groundwork to eventually bring to market an abuse-deterrent, extended-release morphine product.

Advertisement

Related Content

FDA Sticks To Hard Line On Abuse-Deterrent Opioids; Acura Takes A Hit
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register